🎉 M&A multiples are live!
Check it out!

Nanoform Valuation Multiples

Discover revenue and EBITDA valuation multiples for Nanoform and similar public comparables like D&D Pharmatech, Peptron, and LTR Pharma.

Nanoform Overview

About Nanoform

Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceuticals pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications. Geographically, the company generates maximum revenue from Europe, followed by the United States and other regions.


Founded

2015

HQ

Finland
Employees

181

Website

nanoform.com

Financials

LTM Revenue $3.9M

LTM EBITDA -$21.1M

EV

$64.3M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Nanoform Financials

Nanoform has a last 12-month revenue of $3.9M and a last 12-month EBITDA of -$21.1M.

In the most recent fiscal year, Nanoform achieved revenue of $3.0M and an EBITDA of -$21.7M.

Nanoform expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Nanoform valuation multiples based on analyst estimates

Nanoform P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $2.8M $3.0M XXX XXX XXX
Gross Profit $3.4M $1.8M XXX XXX XXX
Gross Margin 123% 62% XXX XXX XXX
EBITDA -$19.2M -$21.7M XXX XXX XXX
EBITDA Margin -695% -727% XXX XXX XXX
Net Profit -$23.7M -$22.3M XXX XXX XXX
Net Margin -860% -747% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Nanoform Stock Performance

As of April 15, 2025, Nanoform's stock price is EUR 1 (or $1).

Nanoform has current market cap of EUR 95.8M (or $103M), and EV of EUR 59.9M (or $64.3M).

See Nanoform trading valuation data

Nanoform Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$64.3M $103M XXX XXX XXX XXX $-0.28

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Nanoform Valuation Multiples

As of April 15, 2025, Nanoform has market cap of $103M and EV of $64.3M.

Nanoform's trades at 16.6x LTM EV/Revenue multiple, and -3.0x LTM EBITDA.

Analysts estimate Nanoform's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Nanoform and 10K+ public comps

Nanoform Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $64.3M XXX XXX XXX
EV/Revenue 21.6x XXX XXX XXX
EV/EBITDA -3.0x XXX XXX XXX
P/E -4.1x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -3.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Nanoform Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Nanoform Valuation Multiples

Nanoform's NTM/LTM revenue growth is 124%

Nanoform's revenue per employee for the last fiscal year averaged $16K, while opex per employee averaged $0.2M for the same period.

Over next 12 months, Nanoform's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Nanoform's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Nanoform and other 10K+ public comps

Nanoform Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 8% XXX XXX XXX XXX
EBITDA Margin -727% XXX XXX XXX XXX
EBITDA Growth 13% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -603% XXX XXX XXX XXX
Revenue per Employee $16K XXX XXX XXX XXX
Opex per Employee $0.2M XXX XXX XXX XXX
S&M Expenses to Revenue 23% XXX XXX XXX XXX
G&A Expenses to Revenue 56% XXX XXX XXX XXX
R&D Expenses to Revenue 56% XXX XXX XXX XXX
Opex to Revenue 951% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Nanoform Public Comps

See public comps and valuation multiples for Drug Delivery Systems comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
LTR Pharma XXX XXX XXX XXX XXX XXX
Starpharma XXX XXX XXX XXX XXX XXX
Schott Pharma XXX XXX XXX XXX XXX XXX
Peptron XXX XXX XXX XXX XXX XXX
D&D Pharmatech XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Nanoform M&A and Investment Activity

Nanoform acquired  XXX companies to date.

Last acquisition by Nanoform was  XXXXXXXX, XXXXX XXXXX XXXXXX . Nanoform acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Nanoform

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Nanoform

When was Nanoform founded? Nanoform was founded in 2015.
Where is Nanoform headquartered? Nanoform is headquartered in Finland.
How many employees does Nanoform have? As of today, Nanoform has 181 employees.
Who is the CEO of Nanoform? Nanoform's CEO is Dr. Edward Haeggstrom.
Is Nanoform publicy listed? Yes, Nanoform is a public company listed on HEL.
What is the stock symbol of Nanoform? Nanoform trades under NANOFH ticker.
When did Nanoform go public? Nanoform went public in 2020.
Who are competitors of Nanoform? Similar companies to Nanoform include e.g. LTR Pharma, Starpharma, Schott Pharma, Peptron.
What is the current market cap of Nanoform? Nanoform's current market cap is $103M
What is the current revenue of Nanoform? Nanoform's last 12-month revenue is $3.9M.
What is the current EBITDA of Nanoform? Nanoform's last 12-month EBITDA is -$21.1M.
What is the current EV/Revenue multiple of Nanoform? Current revenue multiple of Nanoform is 16.6x.
What is the current EV/EBITDA multiple of Nanoform? Current EBITDA multiple of Nanoform is -3.0x.
What is the current revenue growth of Nanoform? Nanoform revenue growth between 2023 and 2024 was 8%.
Is Nanoform profitable? Yes, Nanoform is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.